 Kenneth Malcolm
Concepts (295)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium abscessus | 8 | 2023 | 98 | 3.110 |
Why?
| | Neutrophils | 27 | 2023 | 1163 | 2.830 |
Why?
| | Mycobacterium Infections, Nontuberculous | 12 | 2023 | 333 | 2.190 |
Why?
| | Cystic Fibrosis | 14 | 2023 | 955 | 1.650 |
Why?
| | Host-Pathogen Interactions | 3 | 2020 | 295 | 1.160 |
Why?
| | Azithromycin | 4 | 2020 | 80 | 0.940 |
Why?
| | Phagocytosis | 6 | 2023 | 350 | 0.940 |
Why?
| | Interferons | 2 | 2016 | 151 | 0.860 |
Why?
| | Gene Expression Regulation | 7 | 2020 | 2321 | 0.770 |
Why?
| | Klebsiella pneumoniae | 2 | 2018 | 41 | 0.650 |
Why?
| | Pseudomonas | 1 | 2018 | 26 | 0.640 |
Why?
| | Pseudomonas aeruginosa | 8 | 2022 | 298 | 0.630 |
Why?
| | Lipopolysaccharides | 8 | 2020 | 812 | 0.620 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.590 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 195 | 0.590 |
Why?
| | Anti-Bacterial Agents | 10 | 2022 | 1477 | 0.580 |
Why?
| | Nontuberculous Mycobacteria | 6 | 2023 | 204 | 0.520 |
Why?
| | Pseudomonas Infections | 5 | 2022 | 184 | 0.440 |
Why?
| | Reactive Oxygen Species | 4 | 2020 | 536 | 0.420 |
Why?
| | Staphylococcus aureus | 3 | 2015 | 385 | 0.410 |
Why?
| | Neutrophil Activation | 1 | 2013 | 94 | 0.410 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 61 | 0.410 |
Why?
| | Bacteria | 1 | 2018 | 726 | 0.390 |
Why?
| | Mycobacterium | 1 | 2013 | 103 | 0.380 |
Why?
| | Superoxides | 5 | 2018 | 214 | 0.380 |
Why?
| | Microbial Viability | 3 | 2018 | 79 | 0.330 |
Why?
| | Biofilms | 5 | 2014 | 223 | 0.320 |
Why?
| | Mitogen-Activated Protein Kinases | 4 | 2004 | 278 | 0.300 |
Why?
| | Extracellular Traps | 2 | 2018 | 40 | 0.290 |
Why?
| | Interleukin-8 | 3 | 2020 | 237 | 0.270 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1521 | 0.250 |
Why?
| | Humans | 39 | 2023 | 114756 | 0.240 |
Why?
| | Extracellular Space | 2 | 2018 | 117 | 0.240 |
Why?
| | Cell Separation | 3 | 2016 | 292 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2002 | 743 | 0.230 |
Why?
| | Tobramycin | 4 | 2016 | 47 | 0.210 |
Why?
| | Toll-Like Receptors | 3 | 2017 | 166 | 0.210 |
Why?
| | GTP-Binding Proteins | 1 | 2003 | 139 | 0.200 |
Why?
| | Cytokines | 7 | 2018 | 1843 | 0.200 |
Why?
| | Case-Control Studies | 3 | 2020 | 3005 | 0.200 |
Why?
| | Antimalarials | 1 | 2022 | 24 | 0.200 |
Why?
| | Myelodysplastic Syndromes | 1 | 2023 | 119 | 0.200 |
Why?
| | Primary Cell Culture | 2 | 2020 | 149 | 0.200 |
Why?
| | Pneumonia, Bacterial | 3 | 2013 | 106 | 0.190 |
Why?
| | Bacteriophages | 1 | 2022 | 75 | 0.180 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 21 | 0.180 |
Why?
| | RNA Splicing | 2 | 2023 | 245 | 0.180 |
Why?
| | Chloroquine | 1 | 2020 | 52 | 0.180 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 268 | 0.170 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 4 | 2011 | 262 | 0.160 |
Why?
| | Sirolimus | 1 | 2020 | 181 | 0.160 |
Why?
| | Immunoglobulin G | 1 | 2022 | 774 | 0.150 |
Why?
| | Autophagy | 1 | 2020 | 233 | 0.150 |
Why?
| | Intracellular Space | 1 | 2018 | 68 | 0.150 |
Why?
| | Sputum | 4 | 2022 | 285 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 368 | 0.150 |
Why?
| | Respiratory System | 1 | 2018 | 137 | 0.150 |
Why?
| | Antiviral Agents | 1 | 2003 | 646 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 536 | 0.140 |
Why?
| | Signal Transduction | 3 | 2020 | 4521 | 0.140 |
Why?
| | Aztreonam | 1 | 2016 | 8 | 0.140 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 647 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2018 | 362 | 0.130 |
Why?
| | Survival Analysis | 2 | 2016 | 1218 | 0.130 |
Why?
| | Alternative Splicing | 1 | 2017 | 188 | 0.130 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2539 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2022 | 2557 | 0.120 |
Why?
| | Interferon-alpha | 1 | 2016 | 187 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 301 | 0.120 |
Why?
| | Cell Movement | 4 | 2013 | 867 | 0.120 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2015 | 75 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 493 | 0.120 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2014 | 60 | 0.120 |
Why?
| | Metalloproteases | 1 | 2014 | 37 | 0.120 |
Why?
| | Phagocytes | 1 | 2014 | 90 | 0.120 |
Why?
| | Oxidants | 1 | 2014 | 112 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 815 | 0.110 |
Why?
| | Deoxyribonucleases | 2 | 2011 | 21 | 0.110 |
Why?
| | Mice | 11 | 2023 | 14916 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 71 | 0.110 |
Why?
| | Odds Ratio | 1 | 2016 | 954 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2014 | 142 | 0.110 |
Why?
| | Cell Death | 2 | 2013 | 322 | 0.110 |
Why?
| | Rhinitis | 1 | 2015 | 128 | 0.110 |
Why?
| | Virulence Factors | 1 | 2014 | 139 | 0.110 |
Why?
| | Lung | 7 | 2022 | 3546 | 0.110 |
Why?
| | Wound Infection | 1 | 2013 | 30 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1435 | 0.100 |
Why?
| | Sinusitis | 1 | 2015 | 175 | 0.100 |
Why?
| | Macrophages | 4 | 2023 | 1261 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 2015 | 446 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2011 | 1134 | 0.100 |
Why?
| | Cellular Structures | 1 | 2011 | 3 | 0.100 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 249 | 0.100 |
Why?
| | Contact Lenses, Hydrophilic | 1 | 2011 | 5 | 0.100 |
Why?
| | Lipids | 1 | 2015 | 582 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 225 | 0.100 |
Why?
| | Actins | 3 | 2009 | 381 | 0.090 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2013 | 235 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 310 | 0.090 |
Why?
| | Chemokine CXCL5 | 1 | 2011 | 12 | 0.090 |
Why?
| | Eye Infections, Bacterial | 1 | 2011 | 26 | 0.090 |
Why?
| | Male | 11 | 2022 | 55579 | 0.090 |
Why?
| | Interleukin-17 | 1 | 2011 | 104 | 0.090 |
Why?
| | Viruses | 1 | 2011 | 94 | 0.090 |
Why?
| | Species Specificity | 1 | 2011 | 545 | 0.090 |
Why?
| | Animals | 12 | 2023 | 31761 | 0.080 |
Why?
| | Burns | 1 | 2013 | 237 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 447 | 0.080 |
Why?
| | Mitochondria | 1 | 2014 | 751 | 0.080 |
Why?
| | Peptides | 2 | 2011 | 848 | 0.080 |
Why?
| | Retroviridae | 1 | 2008 | 90 | 0.080 |
Why?
| | cdc42 GTP-Binding Protein | 2 | 2006 | 24 | 0.080 |
Why?
| | Middle Aged | 4 | 2020 | 26757 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2016 | 9089 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 372 | 0.080 |
Why?
| | Transgenes | 1 | 2008 | 170 | 0.070 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2008 | 61 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2013 | 1012 | 0.070 |
Why?
| | Female | 9 | 2020 | 59507 | 0.070 |
Why?
| | Bone Marrow | 1 | 2008 | 244 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2014 | 429 | 0.070 |
Why?
| | Cohort Studies | 2 | 2020 | 4901 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 843 | 0.070 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2007 | 45 | 0.070 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2006 | 73 | 0.070 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 100 | 0.070 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 343 | 0.070 |
Why?
| | Up-Regulation | 3 | 2006 | 812 | 0.070 |
Why?
| | Biomarkers | 3 | 2022 | 3416 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 251 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 40 | 0.060 |
Why?
| | Inflammation | 4 | 2022 | 2481 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 276 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 10463 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1351 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 184 | 0.060 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 954 | 0.060 |
Why?
| | Immunity, Innate | 2 | 2007 | 723 | 0.060 |
Why?
| | Toll-Like Receptor 4 | 2 | 2007 | 286 | 0.060 |
Why?
| | Membrane Microdomains | 1 | 2004 | 32 | 0.060 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 28 | 0.060 |
Why?
| | Enzyme Precursors | 1 | 2003 | 15 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2004 | 58 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2015 | 3542 | 0.060 |
Why?
| | Receptors, CXCR4 | 1 | 2004 | 78 | 0.060 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 16 | 0.060 |
Why?
| | Zymosan | 1 | 2023 | 63 | 0.050 |
Why?
| | Adult | 6 | 2020 | 30548 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 8627 | 0.050 |
Why?
| | Prospective Studies | 3 | 2022 | 6217 | 0.050 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2003 | 8 | 0.050 |
Why?
| | Escherichia coli | 1 | 2007 | 722 | 0.050 |
Why?
| | Bacterial Load | 2 | 2015 | 58 | 0.050 |
Why?
| | eIF-2 Kinase | 1 | 2003 | 24 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | Transcription, Genetic | 3 | 2008 | 1316 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 130 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2003 | 65 | 0.050 |
Why?
| | Toll-Like Receptor 2 | 1 | 2003 | 109 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2005 | 347 | 0.050 |
Why?
| | Interferon Type I | 1 | 2003 | 128 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2003 | 330 | 0.050 |
Why?
| | Gene Expression | 2 | 2008 | 1420 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 250 | 0.050 |
Why?
| | NF-kappa B | 3 | 2013 | 636 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2003 | 173 | 0.050 |
Why?
| | Transcriptional Activation | 2 | 2013 | 337 | 0.050 |
Why?
| | Ciprofloxacin | 2 | 2013 | 23 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 354 | 0.050 |
Why?
| | Mice, Knockout | 3 | 2014 | 2582 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 271 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 398 | 0.040 |
Why?
| | Trans-Activators | 1 | 2003 | 368 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2022 | 642 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2011 | 6350 | 0.040 |
Why?
| | Apoptosis | 2 | 2008 | 2369 | 0.040 |
Why?
| | Neutrophil Infiltration | 2 | 2013 | 94 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 35 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 285 | 0.040 |
Why?
| | Time Factors | 3 | 2018 | 6124 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 10 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 589 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 1951 | 0.040 |
Why?
| | Chemokine CXCL1 | 2 | 2011 | 66 | 0.040 |
Why?
| | Aged | 2 | 2015 | 19094 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 277 | 0.040 |
Why?
| | Drug Administration Routes | 1 | 2016 | 40 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 136 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1314 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 912 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1370 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 184 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2002 | 2763 | 0.030 |
Why?
| | Drug Interactions | 1 | 2016 | 340 | 0.030 |
Why?
| | Cathelicidins | 1 | 2015 | 38 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1796 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 524 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1590 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2014 | 42 | 0.030 |
Why?
| | Gentamicins | 1 | 2015 | 42 | 0.030 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 4710 | 0.030 |
Why?
| | NADPH Oxidases | 1 | 2014 | 120 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 63 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 155 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2008 | 787 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1642 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2011 | 1233 | 0.030 |
Why?
| | PPAR gamma | 1 | 2014 | 182 | 0.030 |
Why?
| | Spleen | 1 | 2015 | 484 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3350 | 0.030 |
Why?
| | Adenoviridae | 1 | 2013 | 185 | 0.030 |
Why?
| | Asthma | 1 | 2005 | 2032 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 292 | 0.030 |
Why?
| | Fibrinogen | 1 | 2013 | 154 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2013 | 220 | 0.030 |
Why?
| | Drug Synergism | 1 | 2013 | 316 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 299 | 0.030 |
Why?
| | Down-Regulation | 2 | 2006 | 596 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2013 | 173 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 503 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 30 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 356 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2387 | 0.020 |
Why?
| | Cell Migration Inhibition | 1 | 2011 | 13 | 0.020 |
Why?
| | Corneal Ulcer | 1 | 2011 | 14 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 37 | 0.020 |
Why?
| | Epithelium, Corneal | 1 | 2011 | 37 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 543 | 0.020 |
Why?
| | Genome | 1 | 2013 | 272 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 928 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 78 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2011 | 129 | 0.020 |
Why?
| | Methacrylates | 1 | 2011 | 106 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 225 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3334 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 430 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 736 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4420 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 78 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4086 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 287 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2013 | 824 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2008 | 84 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 476 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 213 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 157 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2011 | 298 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2007 | 26 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2006 | 52 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 113 | 0.020 |
Why?
| | Child | 2 | 2020 | 18352 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2006 | 78 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2196 | 0.020 |
Why?
| | Keratinocytes | 1 | 2007 | 216 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2005 | 128 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 140 | 0.020 |
Why?
| | Cyclodextrins | 1 | 2004 | 8 | 0.010 |
Why?
| | Vital Capacity | 1 | 2005 | 256 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4409 | 0.010 |
Why?
| | rac GTP-Binding Proteins | 1 | 2004 | 34 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 23 | 0.010 |
Why?
| | Syk Kinase | 1 | 2003 | 18 | 0.010 |
Why?
| | rho GTP-Binding Proteins | 1 | 2004 | 61 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2004 | 74 | 0.010 |
Why?
| | Anthracenes | 1 | 2003 | 27 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2005 | 476 | 0.010 |
Why?
| | Chemokine CCL2 | 1 | 2003 | 105 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1133 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 144 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 3890 | 0.010 |
Why?
| | Dexamethasone | 1 | 2005 | 317 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2004 | 267 | 0.010 |
Why?
| | Chemokines | 1 | 2004 | 213 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 514 | 0.010 |
Why?
| | Cholesterol | 1 | 2004 | 368 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1226 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2639 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 17808 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 101 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2008 | 955 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 1021 | 0.010 |
Why?
| | Ligands | 1 | 2004 | 564 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 450 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 138 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1699 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2003 | 386 | 0.010 |
Why?
| | Imidazoles | 1 | 2002 | 211 | 0.010 |
Why?
| | Homeostasis | 1 | 2004 | 575 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1013 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2118 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 299 | 0.010 |
Why?
| | Pyridines | 1 | 2002 | 425 | 0.010 |
Why?
| | Proteome | 1 | 2002 | 339 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 1988 | 0.010 |
Why?
|
|
Malcolm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|